| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.24 M USD | -12.49 M USD | -6.56 M USD | -3.73 M USD | -3.77 M USD | -3.50 M USD | -3.90 M USD | -4.89 M USD | -5.90 M USD | -5.31 M USD | -4.57 M USD | -3.36 M USD |
| Depreciation & Amortization | 42000 USD | 36000 USD | 13000 USD | 23000 USD | 32000 USD | 32000 USD | 50590 USD | 58789 USD | 67878 USD | 59584 USD | 44891 USD | 34683 USD |
| Stock-Based Compensation | 211000 USD | 173000 USD | 281000 USD | 439000 USD | 223000 USD | 22000 USD | 356218 USD | 705248 USD | 2.67 M USD | 70247 USD | 18013 USD | 50380 USD |
| Capital Expenditures | 96000 USD | 104000 USD | — | 1000 USD | 5000 USD | 53000 USD | 23432 USD | 5371 USD | 19467 USD | 76455 USD | 143736 USD | 63455 USD |
| Cash Flow from Investing | -96000 USD | -104000 USD | — | 1000 USD | -1000 USD | -53000 USD | -23432 USD | -5371 USD | -19467 USD | -76455 USD | -203167 USD | -91513 USD |
| Cash Flow from Financing | 17.04 M USD | 13.74 M USD | 8.73 M USD | — | — | 13.01 M USD | 4.20 M USD | 4.96 M USD | 5.75 M USD | 4.94 M USD | -460863 USD | 6.97 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -15.34 M USD | -12.59 M USD | — | -3.73 M USD | -3.77 M USD | -3.55 M USD | -3.92 M USD | -4.90 M USD | -5.91 M USD | -5.39 M USD | -4.71 M USD | -3.43 M USD |
Glucotrack Inc. is a company dedicated to developing non-invasive glucose monitoring technology. The core purpose of the company is to provide an alternative method for individuals with diabetes to track their blood glucose levels without the need for frequent finger-prick tests. This innovation primarily serves the healthcare and biotechnology sectors, offering a user-friendly solution that aims to improve patient comfort and compliance. The Glucotrack device is designed to measure glucose levels using several physiological parameters detected via an ear clip, conveying real-time data that can be crucial for metabolic management. Its focus on non-invasive technology positions it as a potential game-changer in the realm of diabetic care, especially considering the global prevalence of diabetes. In the broader market context, Glucotrack Inc. represents a significant development within the medtech industry, with its efforts reflecting an ongoing trend towards more patient-centered, convenient healthcare solutions. Its contribution lies not only in its innovative approach but also in its potential to reduce the physical and psychological barriers associated with traditional glucose monitoring methods.